Skip to content


You're viewing the new version of our site. Please leave us feedback.

Learn more

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

  • Joseph P Connor1Email author,
  • Mihaela C Cristea2,
  • Nancy L Lewis3,
  • Lionel D Lewis4,
  • Philip B Komarnitsky5,
  • Maria R Mattiacci6, 9,
  • Mildred Felder1,
  • Sarah Stewart1,
  • Josephine Harter1,
  • Jean Henslee-Downey5,
  • Daniel Kramer7,
  • Roland Neugebauer7 and
  • Roger Stupp8
BMC Cancer201313:20

Received: 14 June 2012

Accepted: 11 January 2013

Published: 15 January 2013

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting

Original Submission
14 Jun 2012 Submitted Original manuscript
29 Aug 2012 Reviewed Reviewer Report - jason chesney
29 Sep 2012 Reviewed Reviewer Report - Michael Morse
19 Oct 2012 Reviewed Reviewer Report - Mayer Fishman
21 Dec 2012 Author responded Author comments - Joseph Connor
Resubmission - Version 2
21 Dec 2012 Submitted Manuscript version 2
11 Jan 2013 Editorially accepted
15 Jan 2013 Article published 10.1186/1471-2407-13-20

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

University of Wisconsin
City of Hope
Kimmel Cancer Center of Thomas Jefferson University
Department of Medicine and The Norris Cotton Cancer Center, Dartmouth Medical School and Dartmouth–Hitchcock Medical Center
EMD Serono Inc
Merck Serono S.A. – Geneva
Merck KGaA
University of Lausanne Hospitals (CHUV)
Presently at Actelion Pharmaceutical Ltd